Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis

Results of a randomized, open label, active-controlled trial in healthy adult volunteers in India

Mysore Kalappa Sudarshan, Doddabele Hanumanthaiah Ashwath Narayana, Shampur Narayan Madhusudana, Ramesh Holla, Belludi Yajaman Ashwin, Bilagumba Gangaboraiah, Haradanahalli S. Ravish

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The currently recommended intradermal regimen for post-exposure prophylaxis spreads over a month period which many times lead to low compliance from the patients. There is a need to introduce and evaluate short course regimens to overcome this problem. This study was conducted to evaluate the immunogenicity and safety of a "new one week intradermal regimen" for rabies post-exposure prophylaxis. A total of 80 healthy adult volunteers were enrolled and allocated randomly either to purified chick embryo cell (PCECV) rabies vaccine or purified verocell rabies vaccine (PVRV), 40 in each group. Each subject received intradermally one of the vaccines, using the one week regimen (4-4-4). Blood samples were collected on Days 0, 7, 14, 28, 180 and 365 for estimation of rabies virus neutralizing antibody (RVNA) concentration. The sera samples were analyzed by rapid fluorescent focus inhibition test (RFFIT). All subjects in both the groups had adequate RVNA concentration of ≥ 0.5 IU/mL from day 14 to till day 180 and the difference of geometric mean concentrations between the two groups was not significant (p > 0.606). Further to assess the immunological memory produced by this new regimen, a "single visit four site" intradermal booster vaccination was given to those who did not have adequate RVNA concentration on day 365. This resulted in a quick and enhanced RVNA concentration in these subjects thus denoting a successful anamnestic response. The incidence of adverse events was 8.3% in PCECV group and 1.6% in PVRV group (p = 0.001) and the regimen was well tolerated without any dropouts. In conclusion, the new "one week intradermal regimen" is immunogenic and safe for rabies post-exposure prophylaxis and needs to be further evaluated in persons exposed to rabies.

Original languageEnglish
Pages (from-to)1077-1081
Number of pages5
JournalHuman Vaccines and Immunotherapeutics
Volume8
Issue number8
DOIs
Publication statusPublished - 01-08-2012

Fingerprint

Post-Exposure Prophylaxis
Rabies virus
Rabies
Rabies Vaccines
Neutralizing Antibodies
India
Healthy Volunteers
Immunologic Memory
Chick Embryo
Patient Compliance
Vaccination
Vaccines
Safety
Incidence
Serum

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Sudarshan, Mysore Kalappa ; Narayana, Doddabele Hanumanthaiah Ashwath ; Madhusudana, Shampur Narayan ; Holla, Ramesh ; Ashwin, Belludi Yajaman ; Gangaboraiah, Bilagumba ; Ravish, Haradanahalli S. / Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis : Results of a randomized, open label, active-controlled trial in healthy adult volunteers in India. In: Human Vaccines and Immunotherapeutics. 2012 ; Vol. 8, No. 8. pp. 1077-1081.
@article{aab6ab7d80534f969e9a8bb36faf9e8d,
title = "Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis: Results of a randomized, open label, active-controlled trial in healthy adult volunteers in India",
abstract = "The currently recommended intradermal regimen for post-exposure prophylaxis spreads over a month period which many times lead to low compliance from the patients. There is a need to introduce and evaluate short course regimens to overcome this problem. This study was conducted to evaluate the immunogenicity and safety of a {"}new one week intradermal regimen{"} for rabies post-exposure prophylaxis. A total of 80 healthy adult volunteers were enrolled and allocated randomly either to purified chick embryo cell (PCECV) rabies vaccine or purified verocell rabies vaccine (PVRV), 40 in each group. Each subject received intradermally one of the vaccines, using the one week regimen (4-4-4). Blood samples were collected on Days 0, 7, 14, 28, 180 and 365 for estimation of rabies virus neutralizing antibody (RVNA) concentration. The sera samples were analyzed by rapid fluorescent focus inhibition test (RFFIT). All subjects in both the groups had adequate RVNA concentration of ≥ 0.5 IU/mL from day 14 to till day 180 and the difference of geometric mean concentrations between the two groups was not significant (p > 0.606). Further to assess the immunological memory produced by this new regimen, a {"}single visit four site{"} intradermal booster vaccination was given to those who did not have adequate RVNA concentration on day 365. This resulted in a quick and enhanced RVNA concentration in these subjects thus denoting a successful anamnestic response. The incidence of adverse events was 8.3{\%} in PCECV group and 1.6{\%} in PVRV group (p = 0.001) and the regimen was well tolerated without any dropouts. In conclusion, the new {"}one week intradermal regimen{"} is immunogenic and safe for rabies post-exposure prophylaxis and needs to be further evaluated in persons exposed to rabies.",
author = "Sudarshan, {Mysore Kalappa} and Narayana, {Doddabele Hanumanthaiah Ashwath} and Madhusudana, {Shampur Narayan} and Ramesh Holla and Ashwin, {Belludi Yajaman} and Bilagumba Gangaboraiah and Ravish, {Haradanahalli S.}",
year = "2012",
month = "8",
day = "1",
doi = "10.4161/hv.20471",
language = "English",
volume = "8",
pages = "1077--1081",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "8",

}

Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis : Results of a randomized, open label, active-controlled trial in healthy adult volunteers in India. / Sudarshan, Mysore Kalappa; Narayana, Doddabele Hanumanthaiah Ashwath; Madhusudana, Shampur Narayan; Holla, Ramesh; Ashwin, Belludi Yajaman; Gangaboraiah, Bilagumba; Ravish, Haradanahalli S.

In: Human Vaccines and Immunotherapeutics, Vol. 8, No. 8, 01.08.2012, p. 1077-1081.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis

T2 - Results of a randomized, open label, active-controlled trial in healthy adult volunteers in India

AU - Sudarshan, Mysore Kalappa

AU - Narayana, Doddabele Hanumanthaiah Ashwath

AU - Madhusudana, Shampur Narayan

AU - Holla, Ramesh

AU - Ashwin, Belludi Yajaman

AU - Gangaboraiah, Bilagumba

AU - Ravish, Haradanahalli S.

PY - 2012/8/1

Y1 - 2012/8/1

N2 - The currently recommended intradermal regimen for post-exposure prophylaxis spreads over a month period which many times lead to low compliance from the patients. There is a need to introduce and evaluate short course regimens to overcome this problem. This study was conducted to evaluate the immunogenicity and safety of a "new one week intradermal regimen" for rabies post-exposure prophylaxis. A total of 80 healthy adult volunteers were enrolled and allocated randomly either to purified chick embryo cell (PCECV) rabies vaccine or purified verocell rabies vaccine (PVRV), 40 in each group. Each subject received intradermally one of the vaccines, using the one week regimen (4-4-4). Blood samples were collected on Days 0, 7, 14, 28, 180 and 365 for estimation of rabies virus neutralizing antibody (RVNA) concentration. The sera samples were analyzed by rapid fluorescent focus inhibition test (RFFIT). All subjects in both the groups had adequate RVNA concentration of ≥ 0.5 IU/mL from day 14 to till day 180 and the difference of geometric mean concentrations between the two groups was not significant (p > 0.606). Further to assess the immunological memory produced by this new regimen, a "single visit four site" intradermal booster vaccination was given to those who did not have adequate RVNA concentration on day 365. This resulted in a quick and enhanced RVNA concentration in these subjects thus denoting a successful anamnestic response. The incidence of adverse events was 8.3% in PCECV group and 1.6% in PVRV group (p = 0.001) and the regimen was well tolerated without any dropouts. In conclusion, the new "one week intradermal regimen" is immunogenic and safe for rabies post-exposure prophylaxis and needs to be further evaluated in persons exposed to rabies.

AB - The currently recommended intradermal regimen for post-exposure prophylaxis spreads over a month period which many times lead to low compliance from the patients. There is a need to introduce and evaluate short course regimens to overcome this problem. This study was conducted to evaluate the immunogenicity and safety of a "new one week intradermal regimen" for rabies post-exposure prophylaxis. A total of 80 healthy adult volunteers were enrolled and allocated randomly either to purified chick embryo cell (PCECV) rabies vaccine or purified verocell rabies vaccine (PVRV), 40 in each group. Each subject received intradermally one of the vaccines, using the one week regimen (4-4-4). Blood samples were collected on Days 0, 7, 14, 28, 180 and 365 for estimation of rabies virus neutralizing antibody (RVNA) concentration. The sera samples were analyzed by rapid fluorescent focus inhibition test (RFFIT). All subjects in both the groups had adequate RVNA concentration of ≥ 0.5 IU/mL from day 14 to till day 180 and the difference of geometric mean concentrations between the two groups was not significant (p > 0.606). Further to assess the immunological memory produced by this new regimen, a "single visit four site" intradermal booster vaccination was given to those who did not have adequate RVNA concentration on day 365. This resulted in a quick and enhanced RVNA concentration in these subjects thus denoting a successful anamnestic response. The incidence of adverse events was 8.3% in PCECV group and 1.6% in PVRV group (p = 0.001) and the regimen was well tolerated without any dropouts. In conclusion, the new "one week intradermal regimen" is immunogenic and safe for rabies post-exposure prophylaxis and needs to be further evaluated in persons exposed to rabies.

UR - http://www.scopus.com/inward/record.url?scp=84866084929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866084929&partnerID=8YFLogxK

U2 - 10.4161/hv.20471

DO - 10.4161/hv.20471

M3 - Article

VL - 8

SP - 1077

EP - 1081

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 8

ER -